DMAC
DiaMedica Therapeutics Inc. · Healthcare
Insiders bought $7.6M of DiaMedica Therapeutics Inc. in the last 12 months
1 insider bought on 1 day.
DMAC over the last year
Largest buyers, last 12 months
DMAC after insider buys
3 months after each buy, from the first price a copier could get.
13 buys since 2018 with 3 months of prices.
Every filing
30 insider filings since 2018, newest first
Jan Stahlberg · 10% owner
Jan Stahlberg · 10% owner
Jan Stahlberg · 10% owner
Koch Thomas Von · 10% owner
Richard Jacinto II · 10% owner
Koch Thomas Von · 10% owner
Jan Stahlberg · 10% owner
Koch Thomas Von · 10% owner
Randall Michael Giuffre · Director
Dietrich John Pauls · President and CEO
Charles Pauling Semba · Director
Scott Kellen · CFO and Secretary
David J. Wambeke · Chief Business Officer
Richard D. Pilnik · Director
David J. Wambeke · Chief Business Officer
Randall Michael Giuffre · Director
Randall Michael Giuffre · Director
Koch Thomas Von · 10% owner
Richard D. Pilnik · Director
Randall Michael Giuffre · Director
Koch Thomas Von · 10% owner
Harry W Alcorn Jr · SVP, Clinical Operations
Amy L. Burroughs · Director
Richard D. Pilnik · Director
Harry W Alcorn Jr · SVP, Clinical Operations
Scott Kellen · CFO and Secretary
Richard D. Pilnik · Director
Randall Michael Giuffre · Director
Richard D. Pilnik · Director
Randall Michael Giuffre · Director
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.